Streetbeat News

Earnings

HA

Hawaiian Holdings projects its capital expenditures for fiscal year 2024 to be between $500 million and $550 million.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 8:04 pm

HA

Hawaiian Holdings projects its Q2 2024 Operating Revenue Per Available Seat Mile (RASM) to range between a decrease of 1.5% and an increase of 1.5%.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 8:04 pm

TXN

Texas Instruments shares are trading higher following a Q1 earnings beat.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 8:03 pm

TXN

Texas Instruments (TXN) projects Q2 revenue to be between $3.65B and $3.95B, compared to the estimated $3.77B. EPS is expected to be in the range of $1.05 to $1.25, against an estimate of $1.16.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 8:03 pm

HA

Hawaiian Holdings (NASDAQ:HA) reported Q1 2024 earnings with an adjusted EPS of $(2.77), missing the $(2.73) estimate, and sales of $645.567M, beating the $629.180M estimate. This represents a 5.38% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 8:02 pm

TXN

Texas Instruments (NASDAQ:TXN) reported Q1 2024 earnings of $1.20 per share, surpassing the $1.08 consensus estimate. Sales reached $3.660B, also beating the $3.611B estimate but marking a 16.42% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 8:01 pm

META

TSLA

Elon Musk, CEO of Tesla and owner of X.com, has seen a significant decline in his net worth due to Tesla's stock price drop, losing his position as the world's richest person. Despite this, Musk's recent endorsement of ARK Invest's positive analysis on Tesla's Q1 expectations and the upcoming Tesla earnings report could influence his financial standing. Meanwhile, Meta Platforms is anticipated to report strong Q1 financial results, potentially impacting its stock.

Portfolio Pulse from Aaron Bry

April 23, 2024 | 7:47 pm

QCOM

Options market activity indicates a bullish sentiment towards Qualcomm (NASDAQ:QCOM), with a significant portion of trades showing expectations for the stock price to range between $120 and $220. Analysis of options trading volume and open interest highlights notable activity, particularly in calls, suggesting liquidity and interest at specific strike prices. Qualcomm's current market status shows a slight increase in stock price to $162.14, with a neutral RSI indicator and an upcoming earnings announcement. Analyst opinions on Qualcomm are mixed but lean towards a positive outlook, with an average price target of $195.4.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 7:00 pm

AAPL

SPOT

Spotify Technology S.A. (NYSE:SPOT) reported record first quarter earnings, surpassing both top and bottom estimates with a 20% YoY revenue increase to 3.64 billion euros and earnings of 97 euro cents per share. The company achieved these results through cost-cutting measures, including layoffs, which led to significant margin improvements. Spotify ended the quarter with 615 million monthly active users, a 19% YoY increase, and 239 million subscribers, up 14% YoY. For the next quarter, Spotify expects 16 million net new MAUs and a gross margin improvement to 28.1%. Additionally, the EU sided with Spotify in its antitrust battle against Apple Inc (NASDAQ:AAPL), fining Apple $1.95 billion for distorting music streaming competition.

Portfolio Pulse from Upwallstreet

April 23, 2024 | 6:58 pm

ANRO

Alto Neuroscience Inc (NYSE:ANRO) reported positive Phase 1 study results for ALTO-101, a PDE4 inhibitor for cognitive impairment in schizophrenia, showing favorable tolerability and pharmacokinetics with a transdermal patch compared to oral administration. The company plans a proof-of-concept study for the first half of 2024, with results expected in 2025. The transdermal delivery showed significantly higher drug concentrations and lower adverse events. William Blair reiterated an Outperform rating on ANRO, highlighting its unique position in neuropsychiatry drug development.

Portfolio Pulse from Vandana Singh

April 23, 2024 | 6:55 pm